- Home
- GAM vs INVA Comparison
GAM vs INVA Comparison
Compare GAM & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAM | INVA |
|---|---|---|
| Founded | 1927 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | N/A | 2004 |
Fundamental Metrics
Financial Performance| Metric | GAM | INVA |
|---|---|---|
| Price | $60.99 | $22.70 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $36.80 |
| AVG Volume (30 Days) | 20.1K | ★ 746.7K |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 5.74% | N/A |
| EPS Growth | N/A | ★ 53.96 |
| EPS | ★ 11.67 | 1.52 |
| Revenue | N/A | ★ $388,521,000.00 |
| Revenue This Year | N/A | $13.23 |
| Revenue Next Year | N/A | $8.58 |
| P/E Ratio | ★ $3.95 | $14.89 |
| Revenue Growth | N/A | ★ 10.14 |
| 52 Week Low | $37.32 | $16.52 |
| 52 Week High | $46.48 | $23.42 |
Technical Indicators
Market Signals| Indicator | GAM | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 54.49 | 72.24 |
| Support Level | $60.00 | $21.55 |
| Resistance Level | $62.01 | $23.42 |
| Average True Range (ATR) | 0.74 | 0.67 |
| MACD | -0.03 | 0.21 |
| Stochastic Oscillator | 48.26 | 69.62 |
Price Performance
Historical ComparisonAbout GAM General American Investors Inc.
General American Investors Co Inc is a closed-end, diversified management investment company. The primary investment objective of the company is long-term capital appreciation through investment in companies with above-average growth potential. It focuses on equity securities with growth potential at reasonable valuations.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalties healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others.